Orchestrating the immune Response
TO Defeat Cancer & Infectious Diseases

Engineering precision immunity

Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer and infectious diseases with potent lymph node targeted immunotherapies and vaccines. Elicio’s Amphiphile platform combines expertise in materials science and immunology  to develop novel immunotherapies and vaccines, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.


Lymph nodes:
where the immune response is orchestrated

Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in early 2021.





Our programs

Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2021. This program consists of an Amphiphile vaccine combined with Elicio’s universal AMP CpG adjuvant (ELI-004) with the potential to elicit powerful immune responses against the seven key KRAS mutations, found in 25% of all solid tumors, including 90% of pancreatic cancers, and 40% of colorectal cancers.



Latest News

Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO
BOSTON, May 1, 2023 – Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced that interim data from the Phase 1 (AMPLIFY-201) study of its lead asset, ELI-002, will be presented in a poster discussion presentation at the upcoming 2023 American Society […] » Read more
Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Lymph Node-Targeted Investigational Therapeutic Vaccine ELI-002 7P (AMPLIFY-7P) in KRAS/NRAS Mutated Solid Tumors
The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of all solid tumors, potentially defeating resistance mechanisms » Read more

Orchestrating the immune system for precision immunity — Download this article to see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.

A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2 Download this presentation